Peter D Feldman

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy
    Mauricio Tohen
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN 46285, USA
    Arch Gen Psychiatry 59:62-9. 2002
  2. ncbi Effect of two different methods of initiating atomoxetine on the adverse event profile of atomoxetine
    Laurence L Greenhill
    The New York State Psychiatric Institute Columbia University, New York 10032, USA
    J Am Acad Child Adolesc Psychiatry 46:566-72. 2007
  3. ncbi Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years
    Peter D Feldman
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychiatry 64:998-1004. 2003
  4. ncbi Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States
    Peter D Feldman
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Am Med Dir Assoc 5:38-46. 2004
  5. ncbi Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone
    Mauricio Tohen
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Br J Psychiatry 184:337-45. 2004
  6. ncbi Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling
    Todd M Sanger
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    J Affect Disord 73:155-61. 2003
  7. ncbi Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms
    Virginia L Stauffer
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Schizophr Res 134:195-201. 2012
  8. ncbi Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia
    Karena M Meehan
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Neuropsychopharmacology 26:494-504. 2002
  9. ncbi Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia
    Walter G Deberdt
    Lilly Research Laboratories, Indianapolis, IN, USA
    Am J Geriatr Psychiatry 13:722-30. 2005
  10. ncbi Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease
    Alan Breier
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Biol Psychiatry 52:438-45. 2002

Detail Information

Publications26

  1. ncbi Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy
    Mauricio Tohen
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN 46285, USA
    Arch Gen Psychiatry 59:62-9. 2002
    ..CONCLUSION: Compared with the use of valproate or lithium alone, the addition of olanzapine provided superior efficacy in the treatment of manic and mixed bipolar episodes...
  2. ncbi Effect of two different methods of initiating atomoxetine on the adverse event profile of atomoxetine
    Laurence L Greenhill
    The New York State Psychiatric Institute Columbia University, New York 10032, USA
    J Am Acad Child Adolesc Psychiatry 46:566-72. 2007
    ..To compare the effects of two different methods for initiating atomoxetine in terms of the incidence of early adverse events...
  3. ncbi Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years
    Peter D Feldman
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychiatry 64:998-1004. 2003
    ..This analysis compares the efficacy of risperidone and olanzapine in controlling negative and positive symptoms of chronic psychosis in older patients...
  4. ncbi Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States
    Peter D Feldman
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Am Med Dir Assoc 5:38-46. 2004
    ..The objective of this study was to investigate risk of diabetes among elderly patients during treatment with antipsychotic medications...
  5. ncbi Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone
    Mauricio Tohen
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Br J Psychiatry 184:337-45. 2004
    ..Aims To evaluate whether olanzapine plus either lithium or valproate reduces the rate of relapse, compared with lithium or valproate alone...
  6. ncbi Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling
    Todd M Sanger
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    J Affect Disord 73:155-61. 2003
    ..CONCLUSIONS: These results indicate that olanzapine was effective in reducing symptoms of mania and well tolerated in patients with bipolar I disorder with a rapid-cycling course...
  7. ncbi Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms
    Virginia L Stauffer
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Schizophr Res 134:195-201. 2012
    ..This distinction, incorporating an evaluation of the presence of positive, affective, and extrapyramidal symptoms, may therefore not have prognostic implications for the responsiveness of patients' negative symptoms to treatment...
  8. ncbi Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia
    Karena M Meehan
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Neuropsychopharmacology 26:494-504. 2002
    ..Intramuscular injection of olanzapine may therefore provide substantial benefit in rapidly treating inpatients with acute dementia-related agitation...
  9. ncbi Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia
    Walter G Deberdt
    Lilly Research Laboratories, Indianapolis, IN, USA
    Am J Geriatr Psychiatry 13:722-30. 2005
    ..The authors compared efficacy of olanzapine versus placebo and risperidone as measured by the Neuropsychiatric Inventory and Clinical Global Impression-Severity of Psychosis scale in patients with dementia-related psychosis...
  10. ncbi Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease
    Alan Breier
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Biol Psychiatry 52:438-45. 2002
    ..Future studies involving gradual dose titration are needed to explore further olanzapine's optimum use for patients with PD with treatment-related psychosis...
  11. ncbi Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia
    Hong Liu-Seifert
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Compr Psychiatry 53:107-15. 2012
    ....
  12. ncbi CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD
    Paula T Trzepacz
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Eur Neuropsychopharmacol 18:79-86. 2008
    ..Results suggest genotyping is unnecessary during routine clinical management, because investigators were able to dose atomoxetine to comparable efficacy and safety levels in EMs and PMs without knowledge of genotype metabolizer status...
  13. ncbi Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia
    Haya Ascher-Svanum
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA
    Neuropsychiatr Dis Treat 8:113-8. 2012
    ..Current findings are consistent with physicians' stated reasons for switching versus augmenting antipsychotics in the treatment of schizophrenia. Confirmation of these findings requires further research...
  14. ncbi Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study
    Richard C Mohs
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Am J Geriatr Psychiatry 17:752-9. 2009
    ..To examine the efficacy and tolerability of atomoxetine (ATX) in improving cognitive performance of patients with Alzheimer dementia...
  15. ncbi Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine
    David P McDonnell
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
    Hum Psychopharmacol 26:422-33. 2011
    ..Metabolic changes in patients with schizophrenia appeared generally similar during treatment with oral olanzapine or olanzapine LAI...
  16. ncbi Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons
    Haya Ascher-Svanum
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    Int J Gen Med 5:391-8. 2012
    ....
  17. ncbi Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data
    Joseph Biederman
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital Harvard Medical School, Yawkey Center for Outpatient Care 6A, Boston, MA 02114, USA
    Psychopharmacology (Berl) 190:31-41. 2007
    ....
  18. ncbi Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia
    Istvan Bitter
    Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary
    Prog Neuropsychopharmacol Biol Psychiatry 28:173-80. 2004
    ..Olanzapine therefore presents a safe alternative in the treatment of refractory schizophrenia...
  19. ncbi Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease
    Peter Paul De Deyn
    Department of Neurology, Middelheim Hospital, University of Antwerp, Antwerp, Belgium
    Int J Geriatr Psychiatry 19:115-26. 2004
    ..5 mg dose was a reasonable starting dose. Olanzapine at 7.5 mg/day significantly decreased psychosis and overall behavioral disturbances (NPI/NH, BPRS) and was well tolerated...
  20. ncbi Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder
    Timothy E Wilens
    Massachusetts General Hospital, Department of Psychiatry, Boston, Massachusetts, USA
    J Pediatr 149:112-9. 2006
    ..To determine the efficacy and safety of atomoxetine in adolescent subjects treated for attention-deficit/hyperactivity disorder (ADHD) for up to 2 years...
  21. ncbi Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment
    Thomas J Spencer
    Massachusetts General Hospital Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
    J Child Adolesc Psychopharmacol 17:689-700. 2007
    ..To examine the effects on growth of long-term pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD), we present findings from an ongoing 5-year study of the efficacy and safety of treatment with atomoxetine...
  22. ncbi Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome
    Thomas J Spencer
    Pediatric Psychopharmacology, Massachusetts General Hospital, Boston, MA 02114 2696, USA
    J Atten Disord 11:470-81. 2008
    ..This study examines changes in severity of tics and ADHD during atomoxetine treatment in ADHD patients with Tourette syndrome (TS)...
  23. ncbi Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study
    Humberto Quintana
    Department of Psychiatry, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, USA
    Clin Ther 29:1168-77. 2007
    ..Recently developed nonpsychostimulant treatments have allowed certain patients to switch from a psychostimulant to a nonpsychostimulant. However, the outcomes of such switches have not been systematically studied...
  24. ncbi Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder
    Christopher J Kratochvil
    University of Nebraska Medical Center, Omaha, NE 68198 5581, USA
    J Am Acad Child Adolesc Psychiatry 45:919-27. 2006
    ....
  25. ncbi Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments
    Kelvin L Chou
    Department of Clinical Neurosciences, Brown Medical School, Providence, Rhode Island, USA
    Clin Neuropharmacol 28:215-9. 2005
    ....
  26. ncbi Atomoxetine and tics in ADHD
    Peter D Feldman
    J Am Acad Child Adolesc Psychiatry 44:405-6. 2005